Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...

Ollin Biosciences has officially launched with $100 million in funding to advance a pipeline of therapies for ...

Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), ...

A new study published in the Journal of American Medical Association found that patients with exudative age-related macular ...

Neil Laird says it is packed with nutrients that protect eyesight and reduce the risk of age-related macular degeneration ...

BrightFocus Foundation today launched two new national public service announcements, Stop AMD and Stop Glaucoma, to raise awareness of macular degeneration and glaucoma, leading causes of irreversible ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

Ollin Biosciences has launched with $100 million in series A financing led by Arch Venture Partners, Mubadala Capital, and ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...